(Revised 1/2023)

blue 🖗 of california

FEP PPO PRESCRIPTION DRUG PRIOR AUTHORIZATION Vyvgart J9332

Plan/Medical Group Name: Blue Shield of California

Plan Phone#: (800) 633-4581

Non-Urgent- The Federal Employee Program has a 72- hour turnaround time on medications that requires Prior Authorization according to the Blue Cross Blue Shield Service Benefit Plan. Failure to complete this form in its entirety may result in delayed processing or an adverse determination for insufficient information FAX TO: <u>844-224-0226</u>

Administration Location: Physician's Office Detient's Home

□ Outpatient Hospital Care

□ Urgent Request- Please note, scheduling issues do not meet the definition of Urgent. <u>Definition of an Urgent Request</u>: An imminent and serious threat to the health of the enrollee; including but not limited to, severe pain, potential loss of life, limb or major bodily function and a delay in decision making might seriously jeopardize the life or health of the member. FAX TO: <u>844-224-0226</u>

Instructions: Please fill out all applicable sections on both pages completely and legibly. Attach any additional documentation that is important for the review, e.g. chart notes or lab data, to support the prior authorization. Information contained in this form is Protected Health Information under HIPAA.									
Patient Information									
First Name:		Last Name:			MI:	F	hone Num	e Number:	
Address:			City:				State:	Zip Code:	
Date of Birth:	□ Male	Circle unit of measure				Allergies:			
	□ Female	Height (in/cm):Weight (lb/kg			-				
Patient's Authorized Representative (if applicable):				Authorized Representative Phone Number:					
Insurance Information									
Primary Insurance Name:				Patient ID Number:					
Secondary Insurance Name:			Patient ID Number:						
Prescriber Information									
First Name		Last Name [.]			Specialty:				

First Name:	Last Name:			Specialty:		
Address:	City:			State:	Zip Code:	
Requestor (if different than prescriber):		Office Contact Person:				
NPI Number (individual):		Phone Number:				
DEA Number (if required):	Fax Number (in HIPAA compliant area):					
Email Address:						
Medication / Medical and Dispensing Information						
Medication Name and HCPCS or CPT Code:						
□ New Therapy □ Renewal If Renewal: Date Therapy Initiated:	Duration of Therapy (specific dates):					
How did the patient receive the medication? Paid under Insurance Name: Prior Auth Number (if known): Other (explain):						
Dose/Strength: Frequency:		Length of ⁻	Therapy/#Refill	s: Qua	ntity:	
Administration:	□ Injection	□IV	□ Other:			

Home Care Agency

Long Term Care

Other (explain):

□ Ambulatory Infusion Center

blue 🖗 of california

PRESCRIPTION DRUG PRIOR AUTHORIZATION

Patient Name:	#:					
Instructions: Please fill out all applicable sections on both pages completely and legibly. Attach any additional documentation that is important for the review, e.g. chart notes or lab data, to support the prior authorization.						
1. Has the patient tried any other medications for this condition? YES (if yes, complete below) NO						
Medication/Therapy (Specify Drug Name and Dosage)	Duration of Therapy (Specify Dates)	Response/Reason f	or Failure/Allergy			
2. List Diagnoses:	-	ICD-10:				
3. Required clinical information - Please provide all relevant clinical information to support a prior authorization or step therapy exception request review.						
Please provide symptoms, lab results with dates and/or justification for initial or ongoing therapy or increased dose and if patient has any contraindications for the health plan/insurer preferred drug. Lab results with dates must be provided if needed to establish diagnosis, or evaluate response. Please provide any additional clinical information or comments pertinent to this request for coverage, including information related to exigent circumstances or required under state and federal laws. Attachments						
Initiation of treatment: 1. Patient is 18 or older ⊡Yes⊡No						

- 2. Diagnosis is Myasthenia Gravis □Yes□No
 - a. Positive serologic test for anti-AChR antibodies □Yes□No
 - b. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IV DYes No
 - c. Documented baseline MG-Activities of Daily Living (MG-ADL) total score \geq 5 with at least 50% of the score due to non-ocular symptoms (https://solirisgmg.com/Content/solirisgmg_com/assets/pdf/MG_ADL_Assessment.pdf) \Box Yes \Box No

d. Patient has had an inadequate treatment response, intolerance, or contraindication to acetylcholinesterase inhibitor and at least ONE immunosuppressive therapy either in combination or as monotherapy, such as: i. azathioprine ii. cyclosporine iii. mycophenolate mofetil iv. tacrolimus v. methotrexate vi. Cyclophosphamide \Box Yes \Box No

e. IgG level \geq 6 grams per liter (g/L) \Box Yes \Box No

f. Prescriber agrees that the patient will be monitored during administration and for one hour after for clinical signs and symptoms of hypersensitivity reactions \Box Yes \Box No

g. Absence of active infection (e.g., urinary tract infection or respiratory tract infection)

Renewal of treatment:

- 1. Patient is 18 or older □Yes□No
- 2. Diagnosis is Myasthenia Gravis □Yes□No
- a. Decrease of MG-ADL total score from baseline of ≥ 2 points \Box Yes \Box No

(https://solirisgmg.com/Content/solirisgmg_com/assets/pdf/MG_ADL_Assessment.pdf)

b. At least 49 days have passed since the start of the previous treatment cycle □Yes□No

c. Prescriber agrees that the patient will be monitored during administration and for one hour after for clinical signs and symptoms of hypersensitivity reactions \Box Yes \Box No

d. Absence of active infection (e.g., urinary tract infection or respiratory tract infection)

(Revised 1/2023)

blue 🗑 of california

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

Date:

Plan/Insurer Use	e Only:	Date/Time Request Received by Plan/Insurer:	Date/Time of Decision
Fax Number ()		
Approved	Denied	Comments/Information Requested:	